LY 309132

Drug Profile

LY 309132

Latest Information Update: 07 Feb 2014

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antihyperlipidaemics; Insulins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 07 Feb 2014 Discontinued - Preclinical for Diabetes mellitus in USA (unspecified route)
  • 09 Feb 2000 No-Development-Reported for Diabetes mellitus in USA (Unknown route)
  • 12 Mar 1997 Preclinical pharmacokinetic data have been added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top